Covid-19: EMA Evaluates Moderna Vaccine Administration From Age 6
The EMA expects to issue an opinion within two months
The EMA expects to issue an opinion within two months
The impact of covid vaccines on the four pharmaceuticals authorized by the European Medicines Agency in stock terms is small
Moderna adds, however, that, "just in case", it is developing a "booster variant" of the vaccine
This approval comes after the EMA Committee on Medicines for Human Use (CHMP) has "exhaustively evaluated the data"
"The EMA Committee for Medicinal Products for Human Use discussion on the [Modern] vaccine was not concluded [on Monday] and will continue on Wednesday."